Biogen’s controversial Alzheimer’s drug made $1.6M in revenue in June

Biotech giant Biogen said Thursday that it brought in about $1.6 million in sales from its controversial Alzheimer’s drug last month after it was approved by the Food and Drug Administration earlier in June.

The drug, which is marketed as Aduhelm, is the first new treatment for Alzheimer’s in about 18 years and the first that doctors are hoping will not just lessen symptoms but target the underlying disease. The company said in its second-quarter earnings report that the drug, which was approved by the FDA on June 7, did $1.6 million in sales before the end of the quarter, which was June 30.